David A. Gerber

Dr. David A. Gerber

Department of Surgery, University of North Carolina, Chapel Hill, NC 27514, USA
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2010 in BioMedical Engineering OnLine
Verified
Journal Article
Open access
PDF file
MSMichael B. Sano
Michael B. Sano
RIRobert Evans Neal II
Robert Evans Neal II
PGPaulo A Garcia
Paulo A Garcia
DGDavid A. Gerber
David A. Gerber
JRJohn L. Robertson
John L. Robertson
Rafael DavalosRafael Davalos
Rafael Davalos
Background: Despite advances in transplant surgery and general medicine, the number of patients awaiting transplant organs continues to grow, while the supply of organs does not. This work outlines a method of organ decellularization using non-thermal irreversible electroporation (N-TIRE) which, in combination with reseeding, may help supplement the supply of organs for transplant. Methods: In our study, brief but intense electric pulses were applied to porcine livers while under active low temperature cardio-emulation perfusion. Histological analysis and lesion measurements were used to determine the effects of the pulses in decellularizing the livers as a first step towards the development of extracellular scaffolds that may be used with stem cell reseeding. A dynamic conductivity numerical model was developed to simulate the treatment parameters used and determine an irreversible electroporation threshold. Results: Ninety-nine individual 1000 V/cm 100-μs square pulses with repetition rates between 0.25 and 4 Hz were found to produce a lesion within 24 hours post-treatment. The livers maintained intact bile ducts and vascular structures while demonstrating hepatocytic cord disruption and cell delamination from cord basal laminae after 24 hours of perfusion. A numerical model found an electric field threshold of 423 V/cm under specific experimental conditions, which may be used in the future to plan treatments for the decellularization of entire organs. Analysis of the pulse repetition rate shows that the largest treated area and the lowest interstitial density score was achieved for a pulse frequency of 1 Hz. After 24 hours of perfusion, a maximum density score reduction of 58.5 percent had been achieved. Conclusions: This method is the first effort towards creating decellularized tissue scaffolds that could be used for organ transplantation using N-TIRE. In addition, it provides a versatile platform to study the effects of pulse parameters such as pulse length, repetition rate, and field strength on whole organ structures.

19 July 2013 in Stem Cells
Verified
Journal Article
Open access
PDF file
GLGiacomo Lanzoni
Giacomo Lanzoni
TOTsunekazu Oikawa
Tsunekazu Oikawa
YWYunfang Wang
Yunfang Wang
CCCai-Bin Cui
Cai-Bin Cui
GCGuido CARPINO
Guido CARPINO
Lola M. ReidLola M. Reid
Lola M. Reid
Regenerative medicine is transitioning into clinical programs using stem/progenitor cell therapies for repair of damaged organs. We summarize those for liver and pancreas, organs that share endodermal stem cell populations, biliary tree stem cells (hBTSCs), located in peribiliary glands. They are precursors to hepatic stem/progenitors in canals of Hering and to committed progenitors in pancreatic duct glands. They give rise to maturational lineages along a radial axis within bile duct walls and a proximal‐to‐distal axis starting at the duodenum and ending with mature cells in the liver or pancreas. Clinical trials have been ongoing for years assessing effects of determined stem cells (fetal‐liver‐derived hepatic stem/progenitors) transplanted into the hepatic artery of patients with various liver diseases. Immunosuppression was not required. Control subjects, those given standard of care for a given condition, all died within a year or deteriorated in their liver functions. Subjects transplanted with 100‐150 million hepatic stem/progenitor cells had improved liver functions and survival extending for several years. Full evaluations of safety and efficacy of transplants are still in progress. Determined stem cell therapies for diabetes using hBTSCs remain to be explored but are likely to occur following ongoing preclinical studies. In addition, mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) are being used for patients with chronic liver conditions or with diabetes. MSCs have demonstrated significant effects through paracrine signaling of trophic and immunomodulatory factors, and there is limited evidence for inefficient lineage restriction into mature parenchymal or islet cells. HSCs' effects are primarily via modulation of immune mechanisms. Stem Cells 2013;31:2047–2060

25 April 2011 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
KSKerri A. Simo
Kerri A. Simo
SSStephanie E. Sereika
Stephanie E. Sereika
KNKimberly N. Newton
Kimberly N. Newton
DGDavid A. Gerber
David A. Gerber

1 August 2006 in Stem Cells
Verified
Journal Article
Closed access
PDF file
MWMaggie H. Walkup
Maggie H. Walkup
DGDavid A. Gerber
David A. Gerber
The field of stem cell biology has exploded with the study of a wide range of cellular populations involving endodermal, mesenchymal, and ectodermal organs. One area of extensive study has included the identification of hepatic stem and progenitor cell subpopulations. Liver stem cells provide insights into the potential pathways involving liver regeneration that are independent of mature hepatocytes. Hepatic progenitor cells are either bipotent or multipotent and capable of multiple rounds of replication. They have been identified in fetal as well as adult liver. Various injury models have been used to expand this cellular compartment. The nomenclature, origin, and function of the hepatic progenitor cell populations are areas of ongoing debate. In this review, we will discuss the different definitions and functions of hepatic progenitor cells as well as the current research efforts examining their therapeutic potential.

2 November 2019 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
KCKatherine S. Cools
Katherine S. Cools
AMAndrew M. Moon
Andrew M. Moon
LBLauren M. B. Burke
Lauren M. B. Burke
KMKatrina A. McGinty
Katrina A. McGinty
PSPaula Strassle
Paula Strassle
DGDavid A. Gerber
David A. Gerber

1 January 2017 in Hepatology
Verified
Journal Article
Closed access
PDF file
PKPaul Kaminsky
Paul Kaminsky
JPJoshua Preiss
Joshua Preiss
ESEizaburo Sasatomi
Eizaburo Sasatomi
DGDavid A. Gerber
David A. Gerber